Mechanism of Action and Biological Profile of HMG CoA Reductase Inhibitors: A New Therapeutic Alternative

Drugs

Volumn 36, Issue 3, 1988, Pages 72-82

  Slater, Eve E ^a,b   MacDonald, James S ^a,b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; COMPACTIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LOW DENSITY LIPOPROTEIN; MEVINOLIN; PRAVASTATIN; PRODRUG; SIMVASTATIN;

ANIMAL EXPERIMENT; ATHEROSCLEROSIS; CELL CULTURE; DOG; DRUG METABOLISM; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MONKEY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RABBIT; RAT; SHORT SURVEY;

ANTICHOLESTEREMIC AGENTS; ARTERIOSCLEROSIS; HUMAN; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; SIMVASTATIN;

EID: 0024150625     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-198800363-00016     Document Type: Article

References (25)

1. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent
2. Ultrastructural analysis of crystalloid endoplasmic reticulum in UT-1 cells and its disappearance in response to cholesterol
3. Brain and optic system pathology in hypocholesterolemic dogs treated with a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase
4. A receptor-mediated pathway for cholesterol homeostasis
5. 3-Hydroxy-methylglutaryl coenzyme A reductase, cleavage and condensing enzymes in relation to cholesterol formation in rat liver
6. Regulation of hepatic receptor-dependent degradation of LDL by mevinolin in rabbits with hypercholesterolaemia induced by a wheat starch-casein diet
7. Detection of familial hypercholesterolaemia by assaying functional low-density lipoprotein receptors on lymphocytes
8. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinum
9. Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin, and pravastatin in rats in vivo (abstract)
10. Familial hypercholesterolemia: identification of a defect in the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity associated with overproduction of cholesterol
11. Inhibition of cholesterol synthesis with compactin renders growth of cultured cells dependent on the low density lipoprotein receptor
12. 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: a new class of cholesterol-lowering agents
13. Lipid metabolism and atherosclerosis
14. Structure elucidation of the bioactive metabolites of ML-236B (Mevastatin) isolated from dog urine
15. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 4. Sidechain ester derivatives of mevinolin
16. Mechanism-based toxicity of HMG-CoA reductase inhibitors in rabbits (abstract)
17. Reduction in incidence of coronary heart disease. Lipid Research Clinics Program. Lipid Metabolism-Atherogenesis Branch. National Heart, Lung and Blood Institute
18. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. Lipid Research Clinics Program. Lipid Metabolism-Atherogenesis Branch. National Heart, Lung and Blood Institute
19. Regulation of HMG-CoA reductase
20. Hydroxymethylglutaryl-coenzyme A reductase-containing hepatocytes are distributed periportally in normal and mevinolin-treated rat livers
21. Hydroxymethylglutaryl-coenzyme A reductase exhibits graded distribution in normal and mevinolin-treated ileum
22. Mevacor, an inhibitor of cholesterol synthesis, induced hydroxymethylglutaryl-coenzyme A reductase directly on membranes of expanded smooth endoplasmic reticulum
23. Efficacy and long-term adverse effect pattern of lovastatin
24. CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibitor of steroid synthesis and hypolipidemic effects on various animal species